Cargando…

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes

Detalles Bibliográficos
Autores principales:	Bianchi, Cristina, Miccoli, Roberto, Daniele, Giuseppe, Penno, Giuseppe, Del Prato, Stefano
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Diabetes and Cardiovascular Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811446/ https://www.ncbi.nlm.nih.gov/pubmed/19875578 http://dx.doi.org/10.2337/dc09-S336

Ejemplares similares

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No
por: Kassem, Sameer A., et al.
Publicado: (2009)

Multidrug Treatment of Type 2 Diabetes: A challenge for compliance
por: Miccoli, Roberto, et al.
Publicado: (2011)

Changing the Treatment Paradigm for Type 2 Diabetes
por: Del Prato, Stefano, et al.
Publicado: (2009)

Is Hyperglycemia a Causal Factor in Cardiovascular Disease?: Does proving this relationship really matter? Yes
por: Davidson, Jaime A., et al.
Publicado: (2009)

Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease
por: Versari, Daniele, et al.
Publicado: (2009)

Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
por: Dardano, Angela, et al.
Publicado: (2021)

Optimal therapy of type 2 diabetes: a controversial challenge
por: Dardano, Angela, et al.
Publicado: (2014)

Hypoglycemia and Cardiovascular Risks
por: Frier, Brian M., et al.
Publicado: (2011)

Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care 2020;43:e139–e141
por: Garofolo, Monia, et al.
Publicado: (2021)

Glucose Control and Cardiovascular Disease: Is it important? No
por: Conget, Ignacio, et al.
Publicado: (2009)

Is Hyperglycemia a Cardiovascular Risk Factor?
por: Pistrosch, Frank, et al.
Publicado: (2011)

Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study
por: Garofolo, Monia, et al.
Publicado: (2020)

Getting to the “Heart” of the Matter on Diabetic Cardiovascular Disease: “Thanks for the Memory”
por: Cefalu, William T., et al.
Publicado: (2016)

Metabolic regulation of GLP-1 and PC1/3 in pancreatic α-cell line
por: Sancho, Veronica, et al.
Publicado: (2017)

Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study
por: Gori, Mauro, et al.
Publicado: (2016)

Cardiovascular mortality trends in Switzerland 1995–2018
por: Sorrentino, Lisa, et al.
Publicado: (2022)

Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study
por: Garofolo, Monia, et al.
Publicado: (2019)

MON-661 Association of 25-Hydroxyvitamin D Serum Levels with Markers of Glycemic Control in Diabetic and Nondiabetic Patients on Maintenance Hemodialysis
por: Falcetta, Pierpaolo, et al.
Publicado: (2020)

The Munich Myocardial Infarction Registry: Translating the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines on diabetes, pre-diabetes, and cardiovascular disease into clinical practice
por: Schnell, Oliver, et al.
Publicado: (2009)

Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report
por: Dardano, Angela, et al.
Publicado: (2022)

MON-170 Low Plasma Glucose Results from Primary Care Are Not Associated with Morbidity, Mortality, or Underlying Hypoglycemic Disorders
por: Linton, Kathryn, et al.
Publicado: (2019)

Sodium and potassium intake and risk of cardiovascular events and all-cause mortality: the Rotterdam Study
por: Geleijnse, Johanna M., et al.
Publicado: (2007)

Household availability of dietary fats and cardiovascular disease and mortality: prospective evidence from Russia
por: Stefler, Denes, et al.
Publicado: (2021)

Influence of high density lipoprotein cholesterol levels on circulating monocytic angiogenic cells functions in individuals with type 2 diabetes mellitus
por: Lucchesi, Daniela, et al.
Publicado: (2018)

Adherence to Hypoglycemic Agents in Type 2 Diabetes Mellitus: A Cross-Sectional Study
por: Khayyat, Yara A, et al.
Publicado: (2022)

Adherence to Oral Hypoglycemic Agents in Hawaii
por: Lee, Rachel, et al.
Publicado: (2005)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo, Eleonora, et al.
Publicado: (2013)

SUN-656 Hypoglycemic Effect of Oral Administered Superoxide Dismutase
por: Liu, Shutao, et al.
Publicado: (2020)

Shifting the Disease Management Paradigm From Glucose: What are the pros?
por: Stirban, Alin, et al.
Publicado: (2009)

A Summary of the ADVANCE Trial
por: Heller, Simon R.
Publicado: (2009)

Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines
por: Gallwitz, Baptist
Publicado: (2009)

Shifting the Disease Management Paradigm From Glucose: What are the cons?
por: Hanefeld, Markolf, et al.
Publicado: (2009)

Postprandial Hyperglycemia and Glycemic Variability: Should we care?
por: Standl, Eberhard, et al.
Publicado: (2011)

Heart in Diabetes: Not Only a Macrovascular Disease
por: Stratmann, Bernd, et al.
Publicado: (2011)

Heart in Diabetes: A Microvascular Disease
por: Laakso, Markku
Publicado: (2011)

Antiplatelet Therapy for Every Diabetic Person?
por: Nicolucci, Antonio, et al.
Publicado: (2011)

Should C-Reactive Protein Be a Target of Therapy?
por: Oh, Jisun, et al.
Publicado: (2011)

Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table
por: Doehner, Wolfram, et al.
Publicado: (2019)

Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond
por: Bretzel, Reinhard G., et al.
Publicado: (2009)

Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review
por: Price, Hilary I, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8u0ocrragq55v1rt4hq3m3f9fc